-
The future of Alzheimer’s treatment
Researchers have discovered that Alzheimer’s disease patients’ brain tissue shows swelling of neurons with swollen lysosomes spilling waste into the brain in both mice and brain tissue. Researchers said the bulging neurons are a sign that the cells’ lysosomal system is dysfunction, which causes waste to accumulate inside cells, ultimately killing them and spilling ready-made…
-
The Great Depression shaped the people’s genes.
The world’s first-ever genome-wide association study, led by the Yottabyte Epigenome Research Group at Rutgers University, found a link between the Yottabyte Epigenome and Alzheimer’s disease, diabetes and leukaemia. It also found a link between the Yottabyte Epigenome pattern and higher rates of disease and deaths in people with diabetes and leukaemia.
-
Is lecanemab the key to changing the course of Alzheimer’s disease?
US’ Food and Drug Administration (FDA) is considering an accelerated approval for a drug to treat Alzheimer’s disease. Leqembi, developed by Biogen and Eisai, reduced marker of amyloid in Alzheimer’s patients’ brains and was associated with less decline in cognitive function than a placebo. The drug is currently being tested in a Phase 3 clinical…
-
Side effects from the Covid-19 vaccine have links to higher antibody response.
The COVID-19 variant Omicron B.4 accounted for almost one in three new infections in the US last week. The variant BA.5 also accounted for 49.6% of new infections in the country, data from the Centers for Disease Control and Prevention (CDC) said. Co-circulating Omicron B.4 has been linked to an increased risk of neurological problems…